ライフサイエンスコーパス: therapeutic range

1 dard of care, warfarin, by improving time in therapeutic range.

2 alation was 331 ng/mL, within the postulated therapeutic range.

3 e or fewer infusions to be maintained in the therapeutic range.

4 ssion, ideally yielding factor levels in the therapeutic range.

5 l normalized ratio (INR) elevation above the therapeutic range.

6 in serum were within or above the suggested therapeutic range.

7 ged delay in return of the INR to within the therapeutic range.

8 tion of genetically corrected cells into the therapeutic range.

9 tion of genetically corrected cells into the therapeutic range.

10 ectively), with more frequent INRs below the therapeutic range.

11 d higher than the defined upper limit of the therapeutic range.

12 in blood levels that deviate from the target therapeutic range.

13 ) but with a substantially broader estimated therapeutic range.

14 ng effects were dose-dependent, with a broad therapeutic range.

15 n up to 1% serum, thus covering the relevant therapeutic range.

16 culatory concentration of drugs within their therapeutic range.

17 rates of anticoagulation and similar time in therapeutic range.

18 hours, maintaining plasma levels within the therapeutic range.

19 was established as the lower margin for the therapeutic range.

20 elevant bleeding followed closely by time in therapeutic range.

21 INR variability, followed closely by time in therapeutic range.

22 e was positively associated with time in the therapeutic range.

23 y is needed to define the lower bound of the therapeutic range.

24 s effectiveness relies on maintaining INR in therapeutic range.

25 at 1 and 3 months and percentage of time in therapeutic range.

26 thromboplastin time (p = .002) close to the therapeutic range.

27 to develop optimal dosing schedules based on therapeutic ranges.

28 ed well with each other and with established therapeutic ranges.

29 adverse outcomes and operating within narrow therapeutic ranges.

30 um drug levels, usually within pre-specified therapeutic ranges.

31 s in whole blood throughout their individual therapeutic ranges.

32 from 0.03 to 0.35 microM, which falls in the therapeutic range (0.01-10 microM), and a limit of detec

33 , (2) intravenous heparin maintained in the "therapeutic" range (0.2 to 0.5 U/mL plasma), and (3) "ex

34 lenges of maintaining serum levels in a safe therapeutic range (1-3muM).

35 than, within, or greater than a prespecified therapeutic range (1.5-2.5 times control), respectively.

36 activity with carbamazepine levels above the therapeutic range (15.4-17.2 mg/ml), but the remaining f

37 he international normalized ratio within the therapeutic range (2.0-3.0) for 6 months.

38 3.5 to 8.4 mg/l, which was within the normal therapeutic range (4-12 mg/l).

39 ts with liver disease had lower mean time in therapeutic range (53.5%) when compared with patients wi

40 h a score of zero had modestly lower time in therapeutic range (56.7%) and no increase in hemorrhages

41 ents were included (mean control-arm time-in-therapeutic-range 60%).

42 in therapeutic range available (mean time in therapeutic range=65.0+/-24.8%).

43 ersus 42% at 3 months; percentage of time in therapeutic range 69% versus 58%, 71% versus 59%, respec

44 Outcomes included percent time in therapeutic range, a measure of anticoagulation control,

45 st human tumor xenografts showed an improved therapeutic range (active/toxic dose in mg/kg body weigh

46 INR more than or equal to the lower limit of therapeutic range, adding either early INRs or genotypes

47 cohort on adalimumab monotherapy, defining a therapeutic range and finding value in early measurement

48 stent warfarin dosing could optimize time in therapeutic range and improve clinical outcomes in atria

49 leeding was a combination of percent time in therapeutic range and INR variability (odds ratio of 4.3

50 red, drug levels generally remain within the therapeutic range and lactate concentrations are not sub

51 However, it has a narrow therapeutic range and the one or more underlying mechani

52 A group were stratified according to time in therapeutic range and time spent with an INR >3.

53 challenging in children because of a narrow therapeutic range and wide inter- and intra-individual v

54 Only 3 studies used a validated aPTT therapeutic range, and 11 studies used a range that incl

55 abolized by cytochrome P450 2C, has a narrow therapeutic range, and is a commonly used antiepileptic

56 mus or cyclosporine levels that exceeded the therapeutic range, and none had other clinical evidence

57 vulsant drug levels in the upper half of the therapeutic range, and were not taking any other drugs t

58 With the narrow therapeutic range associated with most anticancer drugs,

59 h and 3 months and for percentage of time in therapeutic range at 3 months.

60 p 3, 93.4% of the participants had a time in therapeutic range available (mean time in therapeutic ra

61 widely used anticoagulant that has a narrow therapeutic range because of both genetic and environmen

62 ectly classify propofol concentration in the therapeutic range between 1muM and 60muM with levels of

63 ound a significant difference in the time in therapeutic range between the pharmacogenetic and standa

64 acrolimus trough concentrations in the usual therapeutic range can lead to elevated unbound concentra

65 with 0%, 20%, 40%, 60%, 80%, or 100% time in therapeutic range (defined as an SBP between 110 and 130

66 e the optimum anti-Xa heparin activity assay therapeutic range during extracorporeal membrane oxygena

67 The percentage of time in the therapeutic range during the first 4 weeks after the ini

68 As antibiotic concentrations decline below a therapeutic range, filamentous bacteria begin to divide

69 nsitive to methylphenidate, and the accepted therapeutic range for adults is an overshoot.

70 chronic treatment (well within the accepted therapeutic range for adults), produced significant depr

71 An INR of 2 to 3 is the recommended therapeutic range for all indications except for the pre

72 resulted in plasma concentrations within the therapeutic range for calpain inhibition.

73 the test results, and establishment of a PFT therapeutic range for each antiplatelet drug should be c

74 d to 25 mug L(-1) diclofenac) was within the therapeutic range for humans.

75 which declined, but remained above the human therapeutic range for over 9 months.

76 ment learning algorithm can optimize time in therapeutic range for patients taking warfarin.

77 for gamma-globin expression approaching the therapeutic range for sickle cell anemia and beta thalas

78 We hypothesized that the time in therapeutic range for tecarfarin will exceed values usua

79 mL) levels within 30 min and remained in the therapeutic range for the entire 24-h period.

80 olimus trough concentration) and TAC time in therapeutic range for the risk of dnDSAs in a cohort of

81 The time in therapeutic range for the warfarin group was 66%.

82 entrations were still within the recommended therapeutic range for type 2 diabetic patients.

83 canine factor IX (cFIX) concentrations at a therapeutic range for up to 2.5 months and normalization

84 Time in the therapeutic range for warfarin recipients was 58% (inter

85 ernational normalized ratio (INR) was in the therapeutic range from day 4 or 5 through day 28 of ther

86 Study outcomes included optimal time in therapeutic range >/=65% and clinical events.

87 zed ratio control was excellent (time in the therapeutic range >72.6%).

88 C) in patients grouped by pre-switch time-in-therapeutic range guideline thresholds.

89 gh intra-patient variability and low time in therapeutic range) had a high risk of dnDSA (aOR 4.93, 9

90 Time in the therapeutic range has been inversely correlated with maj

91 bjects in group 3, regardless of the time in therapeutic range (hazard ratio ranges=0.53-0.71 and 0.5

92 t block of peak INa at levels well below the therapeutic range (IC50 of 6.8+/-0.4 micromol/L).

93 e initial drug blood serum levels within the therapeutic range in children and adjusted throughout th

94 andard linezolid dosage regimen achieved the therapeutic range in only 54.7% of patients.

95 y and found no difference in the time in the therapeutic range in patients randomized to vitamin K co

96 eased average daily deviation (ADD) from the therapeutic range in patients with: donor CYP3A4*22 GG (

97 nced patients assigned warfarin, the time in therapeutic range (international normalized ratio 2.0 to

98 Time in therapeutic range (international normalized ratio, 2.0-3

99 mortality amongst warfarin users, if time in therapeutic range is poor.

100 activated partial thromboplastin time (aPTT) therapeutic range is required to ensure administration o

101 Cell metformin loads in the therapeutic range lowered cell G6P but not ATP and decre

102 rmalized ratio control was poor (time in the therapeutic range <57.1%).

103 onal normalized ratio control (i.e., time in therapeutic range <65%) exhibited a faster decline in GF

104 t of higher rates of dnDSAs, and TAC time in therapeutic range may be a valuable strategy to stratify

105 of anticoagulation in patients to a set INR therapeutic range may be less secure than anticipated.

106 how that CBZ, at concentrations in the human therapeutic range, normalizes the voltage dependence of

107 Only 10.9% of patients had time in therapeutic range of <45%.

108 TAC time in the therapeutic range of <60% was associated with dnDSAs (OR

109 We recommend a day 0 therapeutic range of 0.2 to 0.4 mug/mL.

110 f response or neurotoxicity by identifying a therapeutic range of 1.5 mg/L (>85% probability of respo

111 me measure was the percentage of time in the therapeutic range of 2.0 to 3.0 for the international no

112 The simulation predicted a mean time in therapeutic range of 70.6% and 72.2% (P=0.47) in the sta

113 A therapeutic range of adalimumab trough levels of 3.51 mg

114 The technique is effective over the therapeutic range of Bevacizumab concentrations.

115 ral nerves, a key finding that increases the therapeutic range of FUS-based peripheral neuromodulatio

116 one demonstrated CsA blood levels within the therapeutic range of human renal transplant patients.

117 n the case of epilepsy because of the narrow therapeutic range of most AEDs; clinical principles of p

118 50%, respectively, but were still within the therapeutic range of preclinical models.

119 in G6PD-deficient individuals to define the therapeutic range of primaquine to enable the safe roll-

120 We also identified the therapeutic range of rAAV.miS1 that could prevent or rev

121 wer at a low current density to increase the therapeutic range of radiofrequency ablation.

122 that the R15E,K156Y mutations may extend the therapeutic range of t-PA.

123 hat PEGylation can significantly improve the therapeutic range of tTF-NGR.

124 useful for the detection of protamine in the therapeutic range of undiluted human blood.

125 Therapeutic ranges of 1.5 to 2.5 times the control value

126 rage duration and control the release of the therapeutic ranges of free radicals required for differe

127 sted drugs, which is sufficient to cover the therapeutic ranges of these drugs.

128 80% in 44 of 48 patients; the median time in therapeutic range on VKA was 50.7%.

129 Mean time in therapeutic range on warfarin was 70.8% (SD 27.4).

130 thium maintenance therapy (lithium levels in therapeutic range) on the rate of change in eGFR over ti

131 Most aPTT values were above therapeutic range or beyond measuring limit and thus of

132 rt continued use of INR variability, time in therapeutic range, or both for research and quality assu

133 a decreased time to the first INR within the therapeutic range (P=0.02) and to the first INR of more

134 ctor of the time to the first INR within the therapeutic range (P=0.57) but was a significant predict

135 atient variability is due to time outside of therapeutic range rather than variability in and of itse

136 atient variability is due to time outside of therapeutic range rather than variability in and of itse

137 n patients with increased individual time in therapeutic range (regression coefficient, 0.03; 95% con

138 (p < .0001 vs. placebo) within or above the therapeutic range, respectively, these did not decrease

139 ess of the age of the patient, where time in therapeutic range should be > or =65%.

140 hat oral methylphenidate at doses within the therapeutic range significantly increases extracellular

141 or IX concentrations, while remaining in the therapeutic range, slowly declined by 95% over a period

142 drug monitoring for drugs that have a narrow therapeutic range such as lithium.

143 s on warfarin and amiodarone had time in the therapeutic range that was lower than patients not on am

144 Our findings suggest that, within its therapeutic range, the effect of olanzapine on relapse o

145 es were the time to the first INR within the therapeutic range, the time to the first INR of more tha

146 der and lithium prescribed within the lowest therapeutic range throughout pregnancy, particularly dur

147 ood and plasma levels were maintained within therapeutic ranges throughout this trial.

148 sensitivity (time to INR >/= lower limit of therapeutic range; time to INR > 4; and first stable war

149 The establishment of a therapeutic range to minimize bleeding and thrombosis is

150 examine the relationship between time in the therapeutic range (TTR) and clinical outcomes in heart f

151 Percent time in therapeutic range (TTR) and international normalized rat

152 patients receiving warfarin, percent time in therapeutic range (TTR) and international normalized rat

153 ntra-patient variability and low TAC time in therapeutic range (TTR) have been associated with risk o

154 intrapatient variability and low TAC time in therapeutic range (TTR) have been associated with risk o

155 BLED could be improved incorporating time in therapeutic range (TTR) in warfarin-treated patients.

156 Time in therapeutic range (TTR) is a crucial metric for assessin

157 Time in therapeutic range (TTR) of BP is associated with cardiov

158 o investigate the impact of warfarin time in therapeutic range (TTR) on results.

159 Time in Therapeutic Range (TTR) was available in only 18.7% of p

160 illation (AF) patients, reflected by time in therapeutic range (TTR).

161 ects in relation to 2 predictions of time in therapeutic range (TTR).

162 comparisons with warfarin arms with times in therapeutic range (TTRs) of 55.2% to 64.9%, making the r

163 te analysis of hydroxyurea levels within the therapeutic range using microliter sample volumes from p

164 4 weeks, the mean percentage of time in the therapeutic range was 45.2% in the genotype-guided group

165 The mean time in the therapeutic range was 53.7% overall and improved with ti

166 patients receiving warfarin, the time in the therapeutic range was 63.5%.

167 The mean percentage of time in the therapeutic range was 67.4% in the genotype-guided group

168 rin treatment, the mean interpolated time in therapeutic range was 71.4%.

169 nternational normalized ratio was within the therapeutic range was higher in the intervention group t

170 patients, the mean percentage of time in the therapeutic range was less in the genotype-guided group

171 anticoagulants when the centre-based time in therapeutic range was less than 66% than when it was 66%

172 Frequency of INR testing and time in the therapeutic range were analyzed by age, sex, length of t

173 first in which concentrations of ASA in the therapeutic range were found to significantly reduce int

174 stemic embolism risk and a lower time in the therapeutic range when used with warfarin.

175 ntra-patient variability and optimal time in therapeutic range), while the latter patients had simila